BioSpace News Archive

Vivera Pharmaceuticals, Inc. is pleased to announce the allowance of its dose-controlled drug delivery device patent for ZICOH®.

Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, and Univercells S.A., a global life sciences company using bioprocessing expertise and next-generation technologies to open access to bioproduction, today announced a research collaboration agreement on an undisclosed

Essenlix Corporation, a premier developer, manufacturer, and provider of mobile instant health test solutions for personal, point-of-care, and clinical use using disruptive and proprietary advanced technology, today announced that it is partnering with Roche Diagnostics Norway to implement Essenlix’s iMOSTTM platform for the Patient At-Home Test market.

PPD, Inc. has been recognized for excellence in the CRO Leadership Awards for the 10th consecutive year, earning praise for its clinical research capabilities and customer compatibility in a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines.

ImmunityBio, Inc today announced an upcoming poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually this year from June 4 through June 8, 2021.

Life-saving initiative will provide pharmaceutical-grade medication as alternative to toxic illegal drug supply during COVID-19 pandemic and beyond

Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai.

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native IL-2 designed to selectively stimulate T regulatory (Treg) cell function

We also received Orphan Designation for NVG-291 from the European Medicines Agency which provides multiple incentives that will assist us in our development program.

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the acquisition of the assets of Geetha, LLC, an adaptive, conversational AI company.